1. Home
  2. KZIA vs IMCC Comparison

KZIA vs IMCC Comparison

Compare KZIA & IMCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KZIA
  • IMCC
  • Stock Information
  • Founded
  • KZIA 1994
  • IMCC 1980
  • Country
  • KZIA Australia
  • IMCC Israel
  • Employees
  • KZIA N/A
  • IMCC N/A
  • Industry
  • KZIA Biotechnology: Pharmaceutical Preparations
  • IMCC Medicinal Chemicals and Botanical Products
  • Sector
  • KZIA Health Care
  • IMCC Health Care
  • Exchange
  • KZIA Nasdaq
  • IMCC Nasdaq
  • Market Cap
  • KZIA 6.0M
  • IMCC 7.5M
  • IPO Year
  • KZIA 1999
  • IMCC N/A
  • Fundamental
  • Price
  • KZIA $0.89
  • IMCC $2.25
  • Analyst Decision
  • KZIA Strong Buy
  • IMCC
  • Analyst Count
  • KZIA 2
  • IMCC 0
  • Target Price
  • KZIA $11.50
  • IMCC N/A
  • AVG Volume (30 Days)
  • KZIA 5.5M
  • IMCC 14.3K
  • Earning Date
  • KZIA 03-26-2025
  • IMCC 03-27-2025
  • Dividend Yield
  • KZIA N/A
  • IMCC N/A
  • EPS Growth
  • KZIA N/A
  • IMCC N/A
  • EPS
  • KZIA N/A
  • IMCC N/A
  • Revenue
  • KZIA $1,655,324.00
  • IMCC $38,042,859.00
  • Revenue This Year
  • KZIA $806.89
  • IMCC $22.59
  • Revenue Next Year
  • KZIA N/A
  • IMCC $32.86
  • P/E Ratio
  • KZIA N/A
  • IMCC N/A
  • Revenue Growth
  • KZIA 248000.00
  • IMCC N/A
  • 52 Week Low
  • KZIA $0.89
  • IMCC $1.61
  • 52 Week High
  • KZIA $15.80
  • IMCC $8.10
  • Technical
  • Relative Strength Index (RSI)
  • KZIA 28.96
  • IMCC 48.95
  • Support Level
  • KZIA $0.90
  • IMCC $2.11
  • Resistance Level
  • KZIA $1.60
  • IMCC $2.42
  • Average True Range (ATR)
  • KZIA 0.24
  • IMCC 0.18
  • MACD
  • KZIA 0.01
  • IMCC 0.01
  • Stochastic Oscillator
  • KZIA 0.00
  • IMCC 36.36

About KZIA Kazia Therapeutics Limited

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.

About IMCC IM Cannabis Corp.

IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.

Share on Social Networks: